High Court · Decided 4 December 2020
Bluestone Corp Pte Ltd v Phang Cher Choon and others and another suit
Feedback & support[2020] SGHC 268 · Case no. Suit No 793 of 2018
✱ What happened, in plain English
There is no plain-English summary of this judgment yet.
Ask about this judgment →Laws this judgment relies on
Grounds of decision
Official text from eLitigation
Introduction
- [1]
[1] The plaintiff in this case is Bluestone Corporation Pte Ltd (“Corporation”), a company incorporated in Singapore on 10 March 1999 and said to be in the business of supplying medical equipment and consumables. Its majority shareholder at all material times was (and continues to be) one Tay Chai Khiang Henry (“Henry”), who was (and continues to be) one of its directors. The first defendant, Phang Cher Choon (“Phang”), was (and continues to be) a minority shareholder in Corporation. Phang was also a director of Corporation up until 24 August 2018, when his employment was terminated. The second defendant, Bluestone Healthcare Sdn Bhd (“Healthcare”), is a company incorporated in Malaysia on 16 February 2004 and said to be in the business of dealing in all kinds of medical products. As at mid-2018 just prior to the filing of the present suit, Phang held 99% of the shares in Healthcare, with the remaining 1% being held by the other director of Healthcare, the third defendant Lim Hooi Loo (“Hooi Loo”). Hooi Loo was also employed by Corporation in its Malaysian branch office from 7 May 2003 until the latter terminated her employment on 24 August 2018.
- [2]
[2] In the present suit, Corporation alleged various breaches of fiduciary duties owed by Phang as its director. Vis-à-vis Hooi Loo, it was alleged that she had breached various terms of her contract of employment with Corporation. The breaches by Phang and Hooi Loo were said to arise primarily from the incorporation of Healthcare in Malaysia in competition with Corporation and their alleged diversion of business or business opportunities from Corporation to Healthcare. Phang, Hooi Loo and Healthcare were also alleged to have engaged in a “conspiracy to defraud” Corporation.
- [3]
[3] The trial before me was not bifurcated as to issues of liability and damage. At the conclusion of the trial, I dismissed Corporation’s claims against all three defendants. As Corporation has filed an appeal, I am setting out below the reasons for my decision. I will first summarise the case advanced by each party and the evidence adduced at trial.
Summary of Corporation’s case and the evidence led in support of its case
Background
- [4]
[4] Corporation’s main witness at trial was Henry. Henry held 65% of the shares in Corporation while Phang held the remaining 35%. The company was founded by both men; and Henry testified that they were its only two executive directors. The company’s operations were split into two divisions – medical equipment and medical consumables. Henry took charge of medical equipment and Phang took charge of medical consumables. In November 2005, Henry’s parents (Tay Buan Say and Sg Wang Kim) were also appointed as directors of Corporation, although Henry claims that they were meant to be “non-executive” directors .
The “ground rules” agreed between Henry and Phang for the management of Corporation’s business – and the incorporation of Absolmed Sdn Bhd
- [5]
[5] According to Henry, when Corporation was set up, he and Phang agreed on a set of “ground rules” for the management of the company’s business. Henry’s version of these “grounds rules” was as follows :
- [6]
[6] Henry claimed that in accordance with these ground rules, when an opportunity to market and sell Sonosite machines in Malaysia came up in 2012, he had informed Phang sometime about it . These machines were already being sold by Corporation in Singapore. Henry claimed that selling the machines in Malaysia would have required Corporation to expand its Malaysian operations by setting up a Sendirian Berhad (“Sdn Bhd”, the Malaysian equivalent of a private limited company); and that when Phang showed a lack of interest in doing so, he had “informed [Phang he] would go ahead to sell Sonosite machines in Malaysia” but that Phang had not responded. Henry then proceeded to set up a Malaysian-registered company called Absolmed Sdn Bhd (“Absolmed”), which dealt with the distributorship of Sonosite until it closed sometime in 2016 or 2017. It was not disputed that Absolmed was for all intents and purposes Henry’s own company, although he did not hold the shares in his name, nor did he have himself appointed as director.
- [7]
[7] As will be seen later, Phang denied that he was informed by Henry about his intention to set up Absolmed to sell Sonosite machines in Malaysia .
Medisol Pte Ltd
- [8]
[8] In March 2006, Corporation set up a company called Medisol Pte Ltd (“Medisol”) offering tele-radiology services in Singapore. Corporation held 75% of the shares in Medisol, with the remaining shares being held by Henry’s friend, one Ernest Phua Eng Tong (“Phua”), through a company called Bridgevision Pte Ltd (“Bridgevision”) . Henry claimed that Phang had refused to get involved in the operations of Medisol and that he had left Henry and Phua to manage this company.
- [9]
[9] Medisol was sold to RadLink-Asia Pte Ltd (“RadLink”) in 2017.
The Malaysian branch office
- [10]
[10] On 20 March 2000, Corporation registered a branch office in Malaysia (“the Malaysian branch office”). As Phang was a Malaysian citizen who spoke fluent Malay, it was agreed that he would oversee the Malaysian branch office . For the purposes of the trial, it was not disputed that the Malaysian branch office is not a Sdn Bhd; and that not being a Sdn Bhd, it cannot accept orders directly from customers in Malaysia. However, the circumstances in which the Malaysian branch office were set up and the objective behind it were a matter of dispute as between Henry and Phang. According to Henry :
- [11]
[11] Henry claimed that it was Phang who had always been unwilling to expand the scope of Corporation’s operations in Malaysia. Indeed, as seen earlier, he claimed it was this refusal on Phang’s part to contemplate the incorporation by Corporation of a Sdn Bhd in Malaysia which had led him to set up Absolmed on his own: his story was that when he approached Phang about the idea of incorporating a Sdn Bhd to market Sonosite machines in Malaysia, Phang had fobbed him off by saying, “… We are not ready yet. Difficult lah, difficult.”
The employment of the third defendant, Hooi Loo
- [12]
[12] A few months after the Malaysian branch office was set up, Hooi Loo – a Malaysian citizen – was hired by Corporation to work in the branch office as a product specialist. Hooi Loo’s contract of employment, which Phang signed on behalf of Corporation, provided, inter alia, as follows :
The breakdown of the relationship between Henry and Phang
- [13]
[13] Henry testified that he and Phang ran their respective divisions – medical equipment (Henry) and medical consumables (Phang) – independently of each other . Moreover, as he found Phang “a forceful personality”, he also sought to “minimise conflict” with Phang by “giv[ing] way” . Corporation’s business was doing well and turning a profit every year – until the year 2016, when the relationship between Henry and Phang started to deteriorate for several reasons .
- [14]
[14] Inter alia, Henry was aggrieved at Phang’s refusal to give a personal guarantee to secure certain bank facilities, and at Phang’s decision to declare bonuses for himself and his team in early 2017 before the finalisation of Corporation’s audited accounts for 2016. When he learnt that Phang had already encashed his bonus cheques, he took back possession of Corporation’s cheque books from Phang . Henry’s sense of grievance against Phang was also increased by discovering – from the accounts forwarded to him by Corporation’s bookkeeper, Chong Yok Fong (“Yok Fong”) – that there was “a sum of more than S$90,000.00/RM300,000.00 in the Malaysian [branch] office’s account”. He felt “disappointed” that Phang had not taken the initiative to transfer this sum to the Singapore office’s account; and in July 2016, he told the latter to transfer S$100,000 from the Malaysian account to Corporation’s Singapore bank account . These incidents paled in comparison, however, to his discovery of the existence of Healthcare and of Phang’s and Hooi Loo’s involvement in Healthcare.
- [15]
[15] In his affidavit of evidence-in-chief (“AEIC”), Henry claimed that he had previously heard some mention of “Bluestone Healthcare” from Yok Fong and another staff, Phua Peck Sian Jasmine (“Jasmine”), but had not inquired into the matter. According to Henry, he had asked Phang about Healthcare on “an occasion early on” after Jasmine mentioned to him that “there was an entity bearing the name ‘Bluestone Healthcare’ in Malaysia”, but when Phang “brushed [him] off” by telling him “you don’t have to know”, he had taken Phang at his word and asked no further questions . As to the fact that Healthcare had been mentioned in Corporation’s audited accounts over the years as a related party , Henry claimed that he had never noticed these references. He said that he was out of the office most of the time and had left it to Phang to give instructions on the preparation of the accounts . He conceded that as Corporation’s director, he had signed off yearly on these accounts, but claimed that he would sign “[a]fter hearing affirmatively from Jasmine or Yok Fong [that Phang] had seen and signed off on the year-end accounts” . He also claimed that he “was not in the practice” of perusing the accounts unless either Phang or Yok Fong brought specific issues to his attention; and neither of them had ever brought to his attention the fact that Healthcare was stated in the accounts to be a related party .
- [16]
[16] Henry claimed that he only “came to know of [Healthcare’s] incorporation, [Phang’s] and [Hooi Loo’s] involvement in [Healthcare], on or after 2.2.2018” – after the new auditor he had engaged for Corporation assisted him to carry out some searches in Malaysia. According to Henry, it was only when he received the search results from the new auditor that he realised for the first time that Phang had set up Healthcare in Malaysia “as far back as 2004”, and that both Phang and Hooi Loo were directors and shareholders of Healthcare .
- [17]
[17] On 9 August 2018, Henry visited Kuala Lumpur together with his brother-in-law David Loh Mun Choong (“David”), his solicitor Mr Martin De Cruz (who subsequently had conduct of the proceedings in the present suit), and a representative from a computer forensics firm. Henry said he was convinced that Healthcare was indeed carrying out business in Kuala Lumpur after David reported to him that the room rented by Corporation’s Malaysian branch office was being occupied by a Healthcare employee and that the “office block business directory disclosed [Healthcare’s] name, but not [Corporation’s]” .
- [18]
[18] On 8 August 2018, prior to visiting Kuala Lumpur, Henry had already filed writs of summonses and statements of claim against all three defendants, although he had yet to serve the papers on them. At that stage, Phang and Healthcare were named as the defendants in the present suit (HC/S 793/2018), while Hooi Loo and Healthcare were named as the defendants in a separate suit (HC/S 794/2018).
- [19]
[19] On 24 August 2018, Henry returned to Kuala Lumpur together with David, who attended at Corporation’s Malaysian office premises with representatives from the computer forensics firm and from Corporation’s Malaysian lawyers. According to David, he had joined Corporation’s employment on 24 August 2018 itself and had been appointed the general manager on the same day . David served on Hooi Loo a notice of termination of employment and also extended her a copy of the writ of summons and statement of claim. Subsequently, Henry met up with Hooi Loo on the same day because he wanted to hear from her about her involvement in Healthcare. Henry claimed that he concluded during their meeting that she had acted with the knowledge that “what she did was wrong” . HC/S 793/2018 was consequently amended to add Hooi Loo as the third defendant, so that Corporation could proceed against all three defendants in the same suit.
- [20]
[20] Phang too was served with a notice of termination of employment on 24 August 2018. His laptop, mobile phone and thumb-drives were seized from him on that day as these were said to belong to Corporation .
Phang’s incorporation of Prius Pte Ltd and Primuz Pte Ltd
- [21]
[21] Henry alleged that it was also after 6 July 2018 that he discovered – through searches done by the company secretary – that Phang had previously incorporated two other companies in Singapore . The first was a company called Prius Pte Ltd (“Prius”) which Phang had incorporated on 18 July 2009. Although Prius had subsequently been struck off the Accounting and Corporate Regulatory Authority (“ACRA”) register in March 2017, Henry said he had found four delivery orders issued by Prius to four entities – the National University of Singapore, Ngee Ann Polytechnic, Impres Trading and Yong Her Sin Medical Store ; and he contended that “[p]roducts sold or sought to be sold by Prius could and should have been sold by [Corporation]”. Moreover, according to Henry, Phang had employed one of Corporation’s employees –Chia Su-Lin Lynnette (“Lynnette”) – in Prius, and this amounted to “us[ing]” her services “to manage his business at Prius” .
- [22]
[22] Secondly, Phang had also incorporated another company called Primuz Pte Ltd (“Primuz”) on 9 February 2017. Henry did not produce any documentary records of sales by Primuz, but his contention was that since the company search on Primuz revealed its principal objects to be “trading of healthcare equipment” , it was “in a position to compete with [Corporation] is [sic] sales of healthcare equipment” . Moreover, Phang had not disclosed to Henry or to Corporation his interests in Primuz and in Prius.
- [23]
[23] I next outline Corporation’s various claims. With respect, these were set out in a rather confusing manner in its amended statement of claim; and the contents of Henry’s AEIC did not always appear to comport with what was pleaded. The summary of Corporation’s claims below is gleaned from its pleadings; and I have also referred to the broad areas or issues on which Henry’s evidence appeared to add to or differ from the pleadings.
Corporation’s claim against Phang for breach of fiduciary duties
- [24]
[24] As against Phang, it was asserted that he owed – in his capacity “as a director and agent of [Corporation]” multiple fiduciary duties, including, inter alia –
(a) a duty to “act bona fide and in good faith in the interest of [Corporation] in the discharge of all duties, powers, responsibilities, obligations and functions assigned to or vested in or attached to [him] as a director of [Corporation]”;
(b) a duty to “serve [Corporation] faithfully and dutifully and not to advance or promote [his] own or other external interests to the prejudice of or contrary to or in conflict with the corporate interests of [Corporation];
(c) a duty “not to place or allow [himself] to be placed in a situation or position whereby any of [his] duties and obligations to [Corporation] conflicted or may conflict with [his] own personal interests”; and
(d) a duty not to make secret profits whilst engaged as a director of Corporation.
- [25]
[25] In addition to such fiduciary duties, it was pleaded that Phang owed Corporation “obligations under the Companies Act Cap 50, under common law and equity, including the duty to exercise reasonable care, to act honestly and use reasonable diligence in the discharge of the office as a director of [Corporation]” .
- [26]
[26] In gist, Corporation claimed that Phang had breached these duties by setting up Healthcare, Prius and Primuz; by using Hooi Loo’s services as a director of Healthcare; by causing Healthcare to compete with Corporation’s business; and by making “secret profits” from Healthcare’s business . Henry’s AEIC added the allegation that Phang had been “self-dealing” by arranging for Healthcare to sell Coeur products to Corporation at prices which were marked up by 15% .
- [27]
[27] Corporation contended that “[i]n the premises”, any “secret profits and/or profits made by [Phang] as a result of his breach of fiduciary duties” were “held on a constructive trust for [Corporation]” . An “account” of such profits was sought. The amended statement of claim did not explain what these “secret profits” might be or how they might have been made. However, in Henry’s AEIC, it was alleged that the “directors’ fees and dividends” received by Phang and/or Hooi Loo from Healthcare over the period from 2004 to 2016 constituted “secret profits” because they had received these payments “surreptitiously” and “unconscionabl[y]” while acting in breach of their “duties of loyalty and fidelity to [Corporation]” . Henry claimed that as Healthcare’s audited accounts over this period showed that they had together received an aggregate amount of RM1,240,000 in directors’ fees and dividends, this was the amount which should be “disgorged” from them.
- [28]
[28] Apart from claiming all “secret profits and/or profits made by [Phang] as a result of his breach of fiduciary duties”, Corporation also claimed the “claw-back” of all bonuses paid to him over the period from 2005 to July 2018, on the grounds that it had paid him these bonuses “as a result of a mistake”, in circumstances where it “did not know [he] was engaged as a director of [Healthcare], acting for the benefit and interests of [Healthcare]” . The bonuses to be clawed back were quantified at $675,000 at para 26 and Schedule 3 of the amended Statement of Claim, but in his AEIC, Henry said that the total amount of bonuses to be clawed back came to $555,000 .
- [29]
[29] In addition, although the recovery of salary payments from Phang was not specifically pleaded in the amended statement of claim, Henry claimed in his AEIC that Corporation was also entitled to damages from Phang “in the form of clawback of part of salaries [paid] out to [him], over the period when [he] was a director of [Healthcare]” [emphasis added] . The salary payments by Corporation to Phang over the period from 2005 to July 2018 totalled $1,723,500 . Henry claimed that Corporation was entitled to claw back 80.31% of this amount, on the basis that an examination of the WhatsApp messages on Phang’s mobile phone had shown that 80.31% of his messages were with Healthcare employees while 19.69% of his messages were with Corporation employees .
- [30]
[30] According to Henry, the basis for seeking claw-back of the remuneration paid to Phang was as follows :
Corporation’s claim against Healthcare for “knowing assistance”
- [32]
[32] It was further pleaded by Corporation that Healthcare had “acted in dishonest and/or knowing assistance” [emphasis added] in relation to Phang’s alleged breaches of fiduciary duties . Elsewhere in the amended statement of claim, it was also pleaded that Healthcare was “liable to account to [Corporation] as a constructive trustee for such profits as were made by [Healthcare] and/or suffered by [Corporation], on the grounds of knowing assistance and receipt” [emphasis added] .
- [33]
[33] In gist, the following particulars were pleaded of the alleged “knowing assistance” :
(a) that Healthcare had “used the services” of both Phang and Hooi Loo;
(b) that Healthcare had operated its business “such as to compete with [Corporation’s] business” and “made unlawful profits from diversion of business away from [Corporation]”;
(c) that Healthcare had passed itself off “as associated with [Corporation]”; and
(d) that Healthcare had used the office premises of Corporation’s Malaysian branch office without the latter’s consent.
- [34]
[34] Henry’s AEIC cited a somewhat different basis for the claim of “knowing assistance”. Henry stated that Healthcare was Phang’s “corporate vehicle in his breach of fiduciary duties”; that Phang was Healthcare’s “controlling mind”; and that Phang had been “assisted in [his] breach” of fiduciary duties by Healthcare “where such assistance was rendered in dishonest circumstances” . Nothing else was said in Henry’s AEIC about the basis for the claim of “knowing assistance”.
Corporation’s claim against Hooi Loo for breach of employment contract
- [35]
[35] Vis-à-vis Hooi Loo, Corporation asserted that in addition to the duties expressly spelt out in her contract of employment, she was also subject to the following “implied” contractual terms :
(a) a duty to “act in the interests of [Corporation]”;
(b) a duty of “loyalty and fidelity to [Corporation]”;
(c) a duty “so long as [her] contract of employment subsisted, not to disclose at any time to any unauthorized individual, any information concerning the interest or business of [Corporation] or any of its subsidiary or associated companies or any of their clients nor make or possess without prior permission, copies of documents, papers or other media on which such information is recorded”;
(d) a duty “not to reveal at any time (whether during the term of employment or after the termination of employment for whatever reason) other than for the use of [Corporation’s] own advantage, or reveal to any person, or company any of the trade secrets, business methods of information [sic] which [she] knew or ought reasonably to have known to be confidential concerning the business or affairs of [Corporation] as far as they would have come to [her] knowledge during [her] employment with the company”; and
(e) a duty “as an employee of the company to obey all applicable laws and practice high ethical standards in [her] dealings with regards to [Corporation’s] affairs”.
- [36]
[36] In gist, Hooi Loo was alleged to have breached her employment contract by joining Healthcare as a director whilst employed by Corporation, by causing Healthcare to compete with Corporation’s business, and by making “secret profits” from Healthcare’s business. She was also alleged to have “caused or allowed” Healthcare to pass itself off as being “associated with [Corporation]” .
- [37]
[37] Similar to its claims against Phang, Corporation also sought against Hooi Loo loosely-framed orders for an “[a]ccount as to damages or equitable compensation for misuse of confidential information, breach of duty and trust, and conspiracy to defraud … and/or an account of secret profits and payments of the sums due and/or damages” . The amended statement of claim did not explain what “secret profits” might have been made by Hooi Loo. However, as noted earlier, it was alleged in Henry’s AEIC that the “directors’ fees and dividends” received by Phang and Hooi Loo from Healthcare between 2004 and 2016 constituted “secret profits”; that the aggregate amount of directors’ fees and dividends paid to them in this period came to RM1,240,000; and that this was the amount they must disgorge .
- [38]
[38] Similar to its claims against Phang, Corporation also sought to claw back from Hooi Loo bonuses totalling $38,100 which it had paid her in the period from 2007 to 2015. The claw-back of these bonuses was said to be premised on their having been paid “as a result of a mistake, in circumstances where [Corporation] did not know [Hooi Loo] was engaged as a director of [Healthcare], acting for the benefit and interests of [Healthcare] in breach of [her] duties to [Corporation]” .
- [39]
[39] In addition, although the recovery of salary payments from Hooi Loo was not specifically pleaded in the amended statement of claim, Henry claimed in his AEIC that Corporation was also entitled to damages from her in the form of claw-back of part of the salaries it had paid her between 2007 and 2017 and between January 2018 and 24 August 2018. The salary payments to Hooi Loo in the period from 2007 to 2017 totalled $379,900, while her salary for the period from January 2018 to 24 August 2018 totalled $26,250 . According to Henry, Corporation was entitled to claw back 84.86% of these amounts. The percentage figure of 84.86%, according to him, was derived as follows : Healthcare’s total revenue over the period from 2011 to 2017 amounted to $4,529,185.13 (converted from Malaysian ringgit) whereas Corporation’s total revenue over the same period amounted to $807,901.92. The aggregate of these two sums came to $5,337,087.05. Since Healthcare’s revenue amounted to 84.86% of this aggregate amount (4,529,185.13 / 5,337,087.05), this must mean that Hooi Loo “spent 84.86% of her time promoting [Healthcare’s] business against 15.14% on [Corporation’s] business”.
- [40]
[40] On top of the monetary reliefs claimed, Corporation also sought against Hooi Loo an injunction to restrain her from “soliciting orders from or otherwise dealing with any customer or agent of [Corporation] for the supply of goods and services of the type sold by [Corporation]” and from disclosing or using “any confidential information acquired by her, during the course of or after her respective period of employment by [Corporation]” . In Henry’s AEIC, nothing was said about the basis on which such injunction was sought.
Corporation’s claims for alleged diversion and/or attempted diversion of business and/or business opportunities
- [41]
[41] In the trial before me, Corporation put forward a number of claims for the alleged diversion and/or attempted diversion of business and/or business opportunities by the defendants. It should be noted that in Corporation’s amended statement of claim, only Healthcare was expressly pleaded as having “diverted business and/or business opportunities away from [Corporation]” , but in Henry’s AEIC , he appeared to include all three defendants in the allegations about the diversion and/or attempted diversion of business and/or business opportunities.
- [42]
[42] The evidence relied on by Corporation for these claims is set out at paras 79–116 of Henry’s AEIC. Per Henry’s AEIC, Corporation claimed that the defendants had diverted and/or attempted to divert business and/or business opportunities from the following companies or entities:
(a) Halyard Health (“Halyard”) (see paras 79–94 of Henry’s AEIC and the exhibits referred to in these paragraphs);
(b) Novatech Resources Pte Ltd (“Novatech”) (see paras 95–101 of Henry’s AEIC and the exhibits referred to in these paragraphs);
(c) Bioteque Corporation (see paras 102–103 of Henry’s AEIC and the exhibits referred to in these paragraphs);
(d) Coeur (see paras 104–105 of Henry’s AEIC and the exhibit referred to in these paragraphs);
(e) Boon syringes (see paras 106–107 of Henry’s AEIC and the exhibits referred to in these paragraphs);
(f) Straumann Singapore (see paras 108–109 of Henry’s AEIC and the exhibits referred to in these paragraphs);
(g) Alliqua (see paras 110–111 of Henry’s AEIC and the exhibit referred to in these paragraphs);
(h) GloTech (see paras 112–113 of Henry’s AEIC and the exhibits referred to in these paragraphs); and
(i) Neos Surgery (see paras 114–116 of Henry’s AEIC and the exhibit referred to in these paragraphs).
- [43]
[43] In gist, Corporation relied on e-mails and other documents retrieved from the electronic devices recovered from Phang for the above claims. I will not reproduce herein the documents referred to in Henry’s AEIC. However, by way of an illustration of the manner in which Corporation’s case was framed and presented, reference may be made to the evidence put forward by Henry to support the allegations about the diversion of business from Halyard. Particular reliance was placed on a set of PowerPoint presentation slides found in Phang’s thumb-drive, which Henry claimed was a “presentation to Halyard” . The presentation included statements about Healthcare being part of a “group” of companies including Corporation and Medisol, about total “group” revenue (in 2014) being S$8m (US$6m), and about the “group” having a total of 26 employees. Henry charged that these statements were “misleading, misrepresentations and a passing off”; and that Halyard’s representative Jace Tan (“Jace”) had become “confused between [Corporation] and [Healthcare]” as evinced from her e-mail exchange with Phang . Henry further charged that Phang and Hooi Loo had “used [Corporation’s] name, reputation and goodwill, to divert and obtain for [Healthcare], the distributorship of Halyard in Malaysia” in or around June/July 2017, and that this had left Corporation having to “start from scratch, after losing everything which was supposed to have been built up for [Corporation’s] Malaysian office” . According to Henry, because Corporation had “lost the opportunity to market and distribute Halyard products in Malaysia” –
- [44]
[44] It should be noted that having apparently quantified Corporation’s loss of Halyard business in terms of Healthcare’s projected total revenue from Halyard sales “over the next six (6) years”, Henry proceeded in his AEIC to frame Corporation’s damages for the loss of Halyard business in terms of the fall in the sales revenue of the Malaysian branch office. According to Henry, after Healthcare obtained the Halyard distributorship in July 2017 –
- [45]
[45] Henry did not specify either in his AEIC or in his testimony whether, in respect of Corporation’s claim for damages resulting from the diversion of Halyard business, the claim for an amount equivalent to Healthcare’s projected total revenue from Halyard sales (over six years) was meant to be an alternative to the claim for an amount equivalent to the Malaysian branch office’s projected cumulative drop in revenue (over six years). Nor did Corporation’s amended statement of claim make clear whether the two were meant to be claims in the alternative.
- [46]
[46] On top of these claims, Henry’s AEIC included further assertions that Corporation was entitled to “general damages” from Healthcare amounting to RM2,362,718 – this amount being apparently Healthcare’s “profits over the period 2011 to 2016 … as appears in [Healthcare’s] Branding Sales Report” . Save for stating that this amount reflected “the profit which should have accrued to [Corporation] over six (6) years from 2016” , Henry did not elaborate on what losses these “general damages” were supposed to recompense. Nor was such elucidation forthcoming in his testimony at trial. It should also be noted that in Henry’s AEIC, this claim for “general damages” was presented as a separate head of claim from the claim for “damages for loss of Halyard business” . However, there was no explanation – either in Henry’s AEIC or in his testimony – as to whether and how the claim for “damages for loss of Halyard business” had been accounted for in Corporation’s quantification of the claim for “general damages”.
- [47]
[47] I should also add that although Henry in his AEIC charged that Phang had diverted to Healthcare business and/or business opportunities from a number of companies apart from Halyard, it was only in respect of the loss of Halyard business that Corporation advanced a claim for damages separate from its claim for general damages. This was despite the fact that Henry cited sales revenue figures for products from several of these other companies: for example, he claimed that Healthcare had “managed to achieve sales of RM17,077.55” for WaterJel R1R2 products from Novatech (citing as his source Healthcare’s Branding Sale Report for the period from January 2018 to July 2018) .
- [48]
[48] I should clarify that it did not appear Healthcare “managed to achieve sales” of products from all of the other companies listed by Henry, as there were several companies for which no evidence of sale or distribution of their products was put forward (for example, Straumann Singapore and Neos Surgery) .
Corporation’s claim for conspiracy to defraud
- [49]
[49] In respect of its claim against all three defendants for what it called “conspiracy to defraud”, Corporation had particularised this claim in its amended statement of claim as Phang having “unlawfully conspired with [Hooi Loo] and [Healthcare]” by, inter alia, setting up Healthcare and causing it to compete with Corporation’s business, using Hooi Loo’s services as a director of Healthcare without Corporation’s consent and without paying Corporation “expenses in the form of salaries, bonuses and remuneration” for the use of her services, using Corporation’s office premises in Malaysia without authorisation, and “attempting to pass-off, deceive and/or lead members of the public to believe [Healthcare] is that of [Corporation] [sic] and/or otherwise connected to or associated with [Corporation]” . However, in a table attached to its amended statement of claim (which was not actually referenced in the amended statement of claim), Corporation set out a somewhat different set of particulars which it labelled “[i]nstances of conspiracy” . These appeared to consist largely of allegations of diversion of “business and/or distribution opportunities” in both Malaysia and Singapore, as well as allegations about the passing off of Healthcare “as [Corporation’s] Malaysian branch to suppliers and/or customers”.
- [50]
[50] In his AEIC, in respect of the claim for conspiracy to defraud, Henry simply referred to those paragraphs in his AEIC which dealt with the alleged diversion and/or attempted diversion of business and/or business opportunities by the defendants .
Corporation’s claim for passing off
- [51]
[51] In respect of its claim for passing off, Corporation pleaded in its amended statement of claim that Healthcare had passed itself off “as associated with [Corporation]” . It also pleaded that Hooi Loo had “caused or allowed” Healthcare to pass itself off “as associated with [Corporation]” . As for Phang, however, the particulars pleaded of his breaches of duties did not mention any involvement on his part in the alleged passing off .
- [52]
[52] Corporation’s amended statement of claim did not plead how the elements of passing off (broadly – goodwill, misrepresentation and damage ) were made out in this case. In his AEIC, Henry claimed that Healthcare had sought to pass itself off “as associated with” Corporation in the following manner. Firstly, according to Henry, a Google search using the search term “Bluestone Healthcare Sdn Bhd” threw up a link which actually led to Corporation’s website . Secondly, the e-mail addresses of Hooi Loo and one Karen Tan (“Karen”, a Healthcare employee) had the e-mail domain “@bluestone.com.my”, whereas Corporation employees’ e-mail addresses had the e-mail domain “@bluestone-corp.com” . Thirdly, Henry said he had uncovered an e-mail sent by Karen to a Corporation staff (Jasmine), in which Karen’s e-mail signature had appeared to represent her to be a Corporation staff (albeit with a Malaysian address) . Fourthly, invoices issued by Healthcare carried the same Malaysian address, telephone and facsimile numbers as Corporation’s Malaysian branch office .
- [53]
[53] According to Henry, the above conduct had created “confusion” by giving “customers and suppliers” the impression that Healthcare was “connected or associated with” Corporation and that Healthcare “sells the same products as [Corporation]” . Henry cited an e-mail by UKM Hospital and an e-mail by Jace (a Halyard staff) which he said showed such confusion. He also cited the evidence of one Lee Jia Shin, who had joined Corporation in March 2019, and who claimed that her encounters with hospitals in Malaysia on “many occasions” since her employment showed that hospital representatives were confused as between Corporation and Healthcare . This confusion, according to Henry, was why Corporation sought “an injunction against the [d]efendants’ use of the ‘Bluestone’ name” .
The alleged use by Healthcare of the office premises of the Malaysian branch office
- [54]
[54] In addition to the claims outlined above, Henry’s AEIC also made various allegations about Healthcare having “passed on” its operational expenses to Corporation by making use of the office premises of Corporation’s Malaysian branch office . The Malaysian branch office had its office address at Suite 12 of Lot C-1/3, Jalam Selaman 1, Dataran Palma, off Jalan Ampang, 68000 Ampang, Selangor Darul Ehsan – a building which parties referred to during the trial as “Weini Business Centre”. In his AEIC, Henry postulated that it was “likely” Healthcare had operated from this office address “from either 2004 or 2007, until on or around 2010/2011”, because Healthcare’s financial statements “made no reference to rentals paid until year 2010” . Henry also alleged in his AEIC that Healthcare had managed in 2011 to take over the office then occupied by Corporation at a lower rate of rental than that previously paid by Corporation. Corporation, in contrast, was said to be paying a higher rate of rental by 2016 .
- [55]
[55] Henry did not explain either in his AEIC or in his testimony how the loss or damage caused to Corporation by Healthcare’s use of its Malaysian office premises should be quantified for the purposes of assessment of damages. Whilst his AEIC did set out a claim for “general damages” from Healthcare, as noted earlier, these were quantified as being an amount equivalent to Healthcare’s “profits over the period 2011 to 2016”.
- [56]
[56] I will next summarise Phang’s and Hooi Loo’s respective defences and the evidence they adduced.
Summary of Phang’s defence and the supporting evidence
The setting up of the Malaysian branch office
- [57]
[57] Phang testified that Corporation’s Malaysian branch office came about primarily because after Corporation had been appointed by Ballard Medical Products (“Ballard”) to distribute some of its medical consumables in Singapore, the latter had expressed interest in having Corporation distribute its products in Malaysia. Ballard was subsequently taken over by the company known as Kimberly-Clark Health Care (“Kimberly-Clark”) which later became known as Halyard. According to Phang, he had informed Henry of Kimberly-Clark’s interest in appointing Corporation as the distributor for some of its products in Malaysia, and he had discussed with Henry the idea of having Corporation incorporate a Sdn Bhd in Malaysia. He had also made it clear to Henry that if they were to incorporate a Sdn Bhd, he (Phang) would have to be the resident director since he was a Malaysian citizen then – and in accordance with the greater liability he would bear, he would wish to be the majority shareholder in this Sdn Bhd. However, Henry – who had from the outset been the majority shareholder in Corporation – was not comfortable with having Phang as the majority shareholder in such a Sdn Bhd .
- [59]
[59] The Malaysian branch office was set up in March 2000. Sometime in early 2003, Corporation was appointed by Kimberly-Clark as the distributor for its test kits and respiratory products in Malaysia. In May 2003, Hooi Loo was hired to run the branch office. The following year, Kimberly-Clark feeding tubes were added to the range of products in Malaysia . Basically, the Malaysian branch office operated as a marketing and liaison office. Hooi Loo would market the products to potential Malaysian customers, but if a Malaysian customer wished to purchase any products, orders could only be taken by the two Malaysian agents, Apex Marketing Sdn Bhd and Nota Tenaga Sdn Bhd, who would then place the orders with Corporation .
The Agreement
- [60]
[60] After some time, according to Phang, Kimberly-Clark began to chase Corporation about its sales figures and to question when Corporation was going to expand its operations in Malaysia. Phang realised that their Malaysian branch office setup was not being taken seriously by Kimberly-Clark . Sometime in 2004, he proposed again to Henry that they should incorporate a Sdn Bhd in Malaysia. Again he told Henry that if such a Sdn Bhd were set up, he (Phang) would have to be the resident director and he would correspondingly wish to be the majority shareholder .
- [61]
[61] Henry was not agreeable to this proposal. Phang asserted that it was around this time that he and Henry came to the “understanding and agreement” which he (Phang) referred to as “the Agreement”. In his amended defence and counterclaim, the Agreement was summarised as follows :
- [62]
[62] In his AEIC and in his testimony in court, Phang elaborated on the Agreement. It will be remembered that Henry had asserted that when they set up Corporation, he and Phang had agreed on a set of “ground rules” for the management of the business . Phang too testified that the two of them had the general understanding or agreement that –
- [63]
[63] According to Phang, this general understanding between them held true for business opportunities in the Malaysian market as well, where it was agreed that each of them “could explore the Malaysian market on [their] own” . This was the Agreement in a nutshell, and it came about after he had approached Henry again in 2004 about incorporating a Sdn Bhd in Malaysia. On that occasion, he had reiterated to Henry that he (Phang) would be its resident director, and as such, he would want to be the majority shareholder in such a Sdn Bhd. Henry did not want Phang to have majority shareholding . Instead, he told Phang that given that Corporation was still a young and small company, it “did not have the capabilities or resources to be able to focus on two separate markets” and should instead focus on the Singapore market . At that point in time, Bluestone’s sales in Singapore were averaging some $2.2m per year, of which at least 56% was attributable to medical consumables – whereas the Malaysian branch office was doing an average of $100,000 to $200,000 in sales per year. When Phang voiced aloud to Henry his worries about their losing the rights to distribute the Kimberly-Clark products in Malaysia, Henry stated that Malaysia did not represent a large part of Corporation’s business and that he did not think it worthwhile for them to pump in more money to develop the Malaysian market, especially since test kits – one of the products they distributed in Malaysia – were a “declining market” anyway .
- [64]
[64] As Henry was not agreeable to Corporation investing in setting up a Sdn Bhd and/or to Phang being the majority shareholder in such a setup, it was decided that they would keep the Malaysian branch office “primarily only to handle the marketing and support with [Corporation’s] Malaysian customers for Respiratory Products, Test Kits and feeding tubes”. Henry told Phang that if he wanted to explore the Malaysian market, then he should go ahead and incorporate a Malaysian company to do so, especially since he was a Malaysian. Phang thought that in view of his Malaysian citizenship and his experience with sales in Malaysia, it would be a good idea for him to do so, in case a business opportunity should present itself . He thus proceeded to incorporate Healthcare on 16 February 2004. He chose the name “Bluestone Healthcare Sdn Bhd” because he did not spend much time thinking of a new name. Moreover, at the back of his mind, he thought that if Henry changed his mind in the future, they could just “absorb Healthcare into [Corporation] as one of its subsidiaries or Henry could purchase the shares in Healthcare” .
- [65]
[65] Phang added that although Healthcare was incorporated in February 2004, it had stayed dormant for a period of time post-incorporation . Sometime in 2005, Henry had asked him whether he had in fact incorporated a company in Malaysia, and he had told Henry about Healthcare while commenting that the company was dormant and that he should put in more effort to explore business opportunities for it .
The termination of Corporation’s right to distribute respiratory products in Malaysia
- [66]
[66] Between 2003 and 2005, the Malaysian sales figures for the Kimberly-Clark respiratory products, test kits and feeding tubes stayed in the range of $100,000 to $200,000 per year. In late 2005, Kimberly-Clark’s then business development manager – one Clara Lee (“Clara”) – announced that Kimberly-Clark had decided to terminate Corporation’s distributorship rights to the respiratory products because they wanted a distributor with “a larger operation and commitment in Malaysia”. Phang felt that this decision to terminate their distributorship for respiratory products was premature, as Corporation had only started distributing these products in Malaysia in 2003 . He wanted to appeal the decision.
The start of Healthcare’s business in Malaysia and Hooi Loo’s involvement
- [68]
[68] Around the same period in late 2005, Corporation also lost its distributorship rights for the Polymem wound dressing product in Singapore. Phang had found another brand called Medifoam which appeared to have a similar product. He decided that before Corporation launched this product in the Singapore market, he would test it out in Malaysia first. This was because the Singapore market was “far more demanding than Malaysia, particularly in terms of quality and results” .
- [69]
[69] According to Phang, he decided to use Healthcare to sell the Medifoam product in Malaysia so as to test where Healthcare’s business might lead. As he had already been working with Hooi Loo and trusted her, he asked her if she wanted to be involved in her free time in Healthcare’s exploration of the Malaysian market with the Medifoam product . He told Hooi Loo that Healthcare was his own company; that Henry was not part of Healthcare; that he was testing the waters with the company at that stage; and that the business of the Malaysian branch office remained her priority . Hooi Loo expressed interest in being involved, and he then left it to her to determine how she would manage her time. When the response to Medifoam in Malaysia appeared positive, Phang introduced the product to Corporation’s repertoire of medical consumables; and Corporation started distributing Medifoam in Singapore in 2007 .
- [70]
[70] When Phang incorporated Healthcare in February 2004, Malaysian law required two Malaysian directors in the company. At that point, Healthcare’s two directors were Phang himself and one Loh Wai Mun. Loh Wai Mun subsequently tendered her resignation in early April 2007, and Phang invited Hooi Loo to come on board as the other director of Healthcare. Hooi Loo joined the Healthcare board on 2 April 2007 . She was given one share in Healthcare when she joined the board (with Phang holding the other 99 shares). Later, when Healthcare’s paid-up share capital was increased from RM100 to RM2,500, Hooi Loo received in 2015 another 24 shares (with Phang holding the other 2,475 shares) .
The further development of Healthcare’s business in Malaysia
- [71]
[71] After the introduction of Medifoam wound dressings, Phang added more items to the range of products distributed by Healthcare in Malaysia. These included not only medical consumables such as Dentium dental implants (in 2007) and Coeur CT scan tubings (in 2010), but also non-medical products such as Chefonic dishwashing chemicals (in 2013) and Nevo cleaning chemicals for restaurants and factories (in 2010) .
- [72]
[72] As Healthcare increased the range of products it distributed to customers in Malaysia, it also employed additional staff; and by 2010, it had an average of “about 3 [staff], including 1 part-time admin and 2 sales personnel” . Phang’s evidence was that there existed a certain degree of loose informality in the work duties of Karen, Healthcare’s part-time administrative staff, as she would help out with the administrative work of Corporation’s Malaysian branch office as and when help was needed .
- [73]
[73] In addition, Phang’s evidence was that if a product distributed by Healthcare in Malaysia did well, he would seek to add it to the range of products distributed by Corporation in Singapore. Thus, besides Medifoam, he also introduced Dentium dental implants and Coeur CT scan tubings into the range of medical consumables distributed by Corporation in Singapore .
Corporation’s knowledge of Healthcare and its business
- [75]
[75] This openness, according to Phang, reflected the fact that Henry – and Corporation – were well aware of the existence of Healthcare, the business it did and Phang’s interest in it . Apart from his having told Henry about his setting up Healthcare to venture into the Malaysian market, and apart from the transparency apparent in the inter-company trades, Phang was frank with all Corporation personnel about having set up Healthcare in Malaysia as his own company. For example, Jasmine – Corporation’s part-time bookkeeping staff from 1999 till January 2018 – gave evidence that in early 2006, when she had sought to clarify with Phang some payments made by Corporation on behalf of Healthcare, Phang had told her that “he set up Bluestone Healthcare in Malaysia” [emphasis added] . When Corporation’s auditors asked about the relationship between Corporation and Healthcare (“Whether it was a subsidiary? Whether Bluestone Corporation owned shares in Bluestone Healthcare? Whether it was a related party?”), Jasmine again approached Phang for answers. Phang’s response was unequivocal :
- [76]
[76] As another example, Corporation sales staff Lynnette testified that in 2006 or 2007, when Phang was planning for Corporation to start selling Dentium dental implants in Singapore, he had told her that he had already achieved “some sales results” for Dentium in Malaysia, through “his Malaysian team”. It was made clear to Lynnette that “this Malaysian team was employed under another business that Phang had set up in Malaysia, separate from [Corporation]” and that Hooi Loo too was involved in this Malaysian business. She subsequently also became aware that Phang’s Malaysian company was called Healthcare.
- [77]
[77] Phang, Hooi Loo and other witnesses also testified that Phang had spoken openly about Healthcare’s sales performance in Malaysia at various events or gatherings when Henry and other Corporation personnel were present. One example was the meeting held on 5 November 2009 as part of Corporation’s tenth anniversary celebrations. During the meeting, Phang and Hooi Loo had given a presentation to all Corporation personnel (including Henry), during which they had spoken, inter alia, about Healthcare’s success in selling Dentium products in Malaysia. Phang could not remember if he had specifically mentioned Healthcare’s name, but he was sure that even if he had not, it would have been obvious to everyone there – including Henry – that he and Hooi Loo had their own business in Malaysia: it was a known fact, after all, that Corporation’s Malaysian branch office did not sell and had never sold Dentium products. Indeed, according to Phang, it was Henry who had suggested that he give a presentation on Healthcare’s success in selling Dentium products in Malaysia, so as “to motivate [Corporation’s] staff to achieve the same level of success as Healthcare” .
- [78]
[78] It was in the same spirit of sharing with and encouraging Corporation staff that Phang and Hooi Loo had continued to speak about Healthcare’s sales experience and sales performance during the regular sales meetings conducted for all Corporation sales staff, administrative personnel and engineers . Henry attended some of these meetings. The information Phang and Hooi Loo shared about Healthcare’s sales was clearly separate from the information they shared about the Malaysian branch office: it was clear that the Malaysian branch office dealt with Kimberly-Clark test kits and feeding tubes; whereas talk about Healthcare’s sales would be about Dentium and Coeur .
- [79]
[79] Phang’s position, therefore, was that consistent with the existence of the Agreement between him and Henry, he had from the outset been open about his venturing into the Malaysian market with the incorporation of Healthcare.
The setting up of Prius and Primuz
- [80]
[80] As for Prius, Phang’s evidence was that he had set up the company in 2009 to test the market in travel-sized hand sanitisers. These travel-sized hand sanitisers were not medical products, and Corporation did not sell hand sanitisers. Lynnette did not take up employment with Prius: she was a 40% shareholder in Prius, and they had regarded their attempt to test the market in these travel-sized hand sanitisers as a “side project” . It was an unsuccessful project as they only managed to sell fewer than five such hand sanitisers over the first few months of Prius’ setting up. Prius ceased operations in 2012 and was struck off in 2017 .
- [81]
[81] As for Primuz, Phang said that he set up the company in 2017 to test the market in Water-Jel burn creams. He had a friend – one Lim Ming Hok (“Ming Hok”) – who was already the distributor of Water-Jel burn creams and who wanted him to try selling these creams . Phang had already tried selling the creams in Malaysia through Healthcare and found the sales results very dismal (“we only managed to sell to one or two customers”) . At that point, Corporation did not sell Water-Jel burn creams or any product similar to these burn creams. Phang wanted to use Primuz to see how the product would do in Singapore. This turned out to be a short-lived experiment, as the creams also did badly in Singapore, with gross sales revenue of just $1,800 between 2017 and 2018 .
The breakdown of the relationship between Henry and Phang: events between 2016 and 2018
- [82]
[82] During the same period, the relationship between Henry and Phang had started to fall apart. Like Henry, Phang too mentioned the fracas over the issue of bonus payments in 2016, but stated that from his point of view, he had not thought there to be anything amiss with preparing a cheque for his usual annual bonus of $50,000 because his team had achieved sales in excess of $1.7m for that year . He was taken aback when Henry angrily refused to counter-sign the cheque for his bonus without offering any explanation, and also when – later that same day – Henry instructed Corporation’s bookkeeper, Yok Fong, to remove all of Corporation’s cheque books from his (Phang’s) office. Up till then, Phang had been responsible for Corporation’s cheque books, and he was not told why Henry had taken the extremely insulting step of ordering their removal from his possession. He perceived that their working relationship was becoming more and more strained but did not at the time really understand why this was so.
- [83]
[83] Because of the increasing tension in their working relationship, Phang did not speak with Henry when in 2017, Jace from Kimberly-Clark – by then rebranded as “Halyard” – informed him that their company was not happy with the arrangements made by Corporation in Malaysia for the distribution of Halyard’s products. As the Malaysian branch office could not sell directly to customers, orders were taken by its Malaysian agents; and Halyard found these arrangements unsatisfactory . Jace told Phang that Halyard would be agreeable to letting the Malaysian branch office continue to distribute its test kits, as they had no issue with the Malaysian agent responsible for this product – but that they wanted Healthcare to take over the distribution in Malaysia of the feeding tubes . As Halyard was adamant about changing distributors for its feeding tubes, Phang agreed to Jace’s request. In his view, “[i]n this way, at least the Branch Office retained the Test Kits business and Healthcare could take over the feeding tubes business which would have ended up elsewhere anyway” .
- [84]
[84] During the trial, Phang testified that he did not talk to Henry about the above change because by then, he would generally be given the brush-off whenever he tried to talk to Henry; and in anger, he had decided to ignore Henry too . However, although he did not speak to Henry about this change in the Malaysian distributorship of Halyard feeding tubes, he did not hide it from Corporation’s employees .
- [85]
[85] It was around this time that Corporation’s subsidiary, Medisol, was sold to RadLink . The sale proceeds of some $10.78m were received by Corporation in 2018. Despite being a 35% shareholder of Corporation, Phang did not receive – and has to date not received – any part of these sale proceeds. On 24 August 2018, his directorship and employment were abruptly terminated by Corporation. On the same day, Corporation’s solicitors also came to the office where they served him with the papers for this suit and seized his laptop and mobile phone .
- [86]
[86] According to Phang, he was blindsided by this turn of events . He was also pained by the ignominious manner in which he had been forced out of Corporation and the false claims laid against him by Henry. Henry had, after all, been aware of his incorporating Healthcare so as to venture into the Malaysian market. Henry himself had set up Absolmed in 2013 to sell Sonosite machines in Malaysia; Phang’s evidence was that he was not in fact informed about Absolmed and only found out about it in 2015, but he did not enquire further as he viewed Henry’s setting up of Absolmed as being consonant with their common understanding that they could each explore the Malaysian market on their own. Henry had also been aware of all that he (Phang) had done for Corporation. Even after Healthcare started trading in Malaysia in 2007, Corporation’s annual revenue from medical consumables had grown between 2007 and 2012, from $1,385,417 to $2,233,073. This figure had dropped after 2013 when Corporation lost the Dentium account in Singapore (an account which Healthcare had also lost in Malaysia). However, Corporation’s revenue from medical consumables had continued to average around $1,724,486.25 between 2013 and 2016 .
- [87]
[87] Phang believed that it was the successful sale of Medisol – and the prospect of having to share the proceeds – which gave rise to Henry’s decision to bring false claims against him . He felt vindicated in his belief when – at an annual general meeting of Corporation on 29 August 2019 – Henry declined to pay out the proceeds from the sale of Medisol. Instead, Henry suggested that there were plans to invest at least $6m of the cash held by Corporation for “investments” but declined to give details of what these investments were .
Defences relied on by Phang
- [88]
[88] In summary, therefore, Phang asserted that having regard to the Agreement between him and Henry (the only two shareholders of Corporation at the material time), he had not breached any fiduciary duties vis-à-vis Corporation in setting up Healthcare and running its business in Malaysia. Even assuming there had been any breaches on his part, Phang also pleaded reliance on the defence of acquiescence ; further and in the alternative, on the defence of time bar, on the basis that Corporation’s causes of action had accrued since 2004 or alternatively no later than 2006, and that its claims were thus time-barred pursuant to s 6(1)(a) and/or s 24A of the Limitation Act (Cap 163, 1996 Rev Ed) .
- [89]
[89] As to Prius and Primuz, Phang asserted that they did not compete with Corporation in terms of the business carried out, and that he had not breached any fiduciary duties to Corporation in setting up these two companies .
- [90]
[90] Further or in the alternative, Phang pleaded that even if he had committed any breaches of his fiduciary duties, he was entitled under s 391 of the Companies Act (Cap 50, 2006 Rev Ed) to seek relief from any liability, on the basis that he had acted honestly and reasonably and ought fairly to be excused for any default or breach .
- [91]
[91] Finally, Phang also challenged Corporation’s claims to various types or heads of damages and for claw-back of salary payments and bonuses .
Phang’s counterclaim
- [92]
[92] In so far as the termination of his directorship and employment was concerned, Phang stated that this had been carried out in a manner “calculated to cause [him] maximum embarrassment and create an environment of fear of any association with [him] in the office” . More importantly, the termination had been effected without any notice being given. In his amended defence and counterclaim, Phang pleaded that it was an implied term of his employment with Corporation that his employment should be determinable only by reasonable notice . He contended that given his responsibilities as a director and his years of experience, a reasonable notice period would have been 12 months . This formed the basis of his counterclaim against Corporation for the sum of $192,240 (being his salary and employer’s Central Provident Fund (“CPF”) contribution for 12 months from 24 August 2018) .
Summary of Healthcare’s defence and the supporting evidence
- [93]
[93] Phang’s evidence provided much of the basis for Healthcare’s defence to Corporation’s various claims. In its amended defence, Healthcare pleaded that Phang had not acted in breach of his fiduciary duties to Corporation, and that it could not therefore be liable for any “dishonest and/or knowing assistance”. In particular, it was pleaded that the existence of Healthcare, its business, and its use of Phang’s and Hooi Loo’s services had all been known to Corporation; further, that Corporation had not raised any objections . Healthcare also denied that its business competed with Corporation’s or that it had diverted to itself business or business opportunities which should have been Corporation’s . As to the claim that it had passed itself off as “being associated with [Corporation]”, this too was denied by Healthcare .
- [94]
[94] Further and in the alternative, like Phang, Healthcare also pleaded estoppel by acquiescence and/or time bar pursuant to s 6(1)(a) and/or s 24A of the Limitation Act .
- [95]
[95] Finally, Healthcare also challenged Corporation’s claims to various types or heads of damages .
Summary of Hooi Loo’s defence and the supporting evidence
- [96]
[96] Like Phang, Hooi Loo asserted that the claims brought by Corporation were trumped-up.
How Hooi Loo came to be involved in Healthcare
- [97]
[97] Hooi Loo joined Corporation as a product specialist on 7 May 2003, on a basic salary of $2,200 per month (with some allowance payments for transport and mobile phone). A Malaysian citizen, she was based in Corporation’s Malaysian branch office. She reported directly to Phang . As for Henry, although she did not report to him on a daily basis, she understood that he too was “involved in the strategic business decisions of [Corporation] and the [Malaysian] branch office” . She herself was “a mere sales employee” of Corporation’s, had no involvement in its business decisions, and denied owing it any fiduciary duties.
- [98]
[98] Hooi Loo was aware that the Malaysian branch office “had a restricted scope due to the nature of its corporate personality” : under Malaysian law, medical products could not be sold to end-users in Malaysia unless the entity selling them was a Sdn Bhd, and had obtained the requisite licences and approvals from the relevant Malaysian authorities . As such, although Hooi Loo was responsible for marketing products to customers in Malaysia, orders had to be taken by the two independent Malaysian “sub-distributors” that Corporation worked with (Nota Tenaga Sdn Bhd and Apex Pharmacy Marketing Sdn Bhd), who would then place these orders with Corporation . Due to these limitations, Kimberly-Clark was the only supplier which the Malaysian branch office had secured; and Hooi Loo’s job with the branch office from the outset was to market Kimberly-Clark product lines. These were: test kits; respiratory products; and feeding tubes . On top of her salary, when Hooi Loo achieved the sales targets set by Corporation, she was paid a commission. Throughout her employment with Corporation, she had usually succeeded in achieving these sales targets .
- [99]
[99] Sometime in 2007, Phang told Hooi Loo about Healthcare and asked her to start selling products on behalf of Healthcare. She was not given a separate employment contract with Healthcare. She claimed that she had the impression the work to be done in respect of Healthcare was under the auspices of Corporation , but it was clear that soon after asking her to sell products on behalf of Healthcare, Phang also asked her to come on board as a director of Healthcare . In April 2007, she was appointed as a director of Healthcare. According to Hooi Loo, this was because Healthcare’s other director besides Phang (one Loh Wai Mun) had resigned, and the company needed to satisfy Malaysian regulatory requirements that the company have two Malaysian directors . Hooi Loo’s position was that she took on the directorship after being reassured by Phang that she would merely be a nominee director, and that the allotment of one Healthcare share to her had also been in compliance with Malaysian regulatory requirements. Her shareholding was subsequently increased to 25 shares in 2015 when Healthcare increased its paid-up capital from RM100 to RM2,500 . Her appointment as director and her shareholding notwithstanding, Hooi Loo asserted that she was “never responsible for the financial management or business management” of Healthcare .
The scope of Healthcare’s business
- [100]
[100] In so far as the distribution of products by Healthcare was concerned, Hooi Loo’s evidence was that these were largely different from the products distributed by Corporation in Singapore and handled in Malaysia by the Malaysian branch office . Moreover, Phang had told her from the outset to “prioritize the marketing of [Corporation’s] products” . She did not think there was “any competition or conflict of interests between [Corporation] / [Corporation’s] branch office and [Healthcare]” . As noted earlier, because of regulatory strictures, the Malaysian branch office could not sell directly to Malaysian end-users and was responsible for marketing only three Kimberly-Clark product lines. In contrast, as a Sdn Bhd, Healthcare was able to sell directly to end-users and thus had a wider range of distributorships. These included medical products such as Medifoam wound dressings, Dentium dental implants and Coeur tubings, as well as non-medical products such as Syntech cleaning chemicals (for cleaning factories and restaurants) and UAL Zymo Biogrow organic fertilisers. Healthcare even offered rental of dishwashing machines from Chefonic Kitchen Equipment . Hooi Loo was certain that –
Corporation’s knowledge of Healthcare and its business
The judgment continues past this page. Read the rest at eLitigation.